Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,716.09
(
0.25%
)
US TECH 100
24,131.60
(
0.48%
)
Dow Jones
46,993.26
(
0.10%
)
Brent Oil
101.20
(
2.95%
)
Bitcoin
74,452.06
(
-0.52%
)
News Focus
News Focus
Post# of 257253
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122793
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: pollyvonwog post# 116045

Monday, 03/07/2011 5:56:43 PM

Monday, March 07, 2011 5:56:43 PM

Post# of 257253

..if indeed it turns out to be preemptive, why wouldn't Sandoz/MNTA have done it earlier?

As noted in #msg-60686112, injected drugs typically don’t need bioequivalence studies; hence, NVS/MNTA may have deferred running such a study until they could ascertain that this matter is on the critical path.

It's also my understanding that these studies are pretty small…

Yes—small and quick.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now